Angelini inks $4.1B Catalyst takeover to fuel US expansion
Florida-based Catalyst markets rare neuromuscular and neurological disease treatments that generated sales of $589 milli…
InflaRx attracts strong investor interest with US share offering turning to kidney
The German biotech company InflarX N.V., which is listed on Nasdaq, is pushing ahead with a strategic repositioning of i…
Scarlet raises £3.2 million to advance lab-grown red blood cell therapies
Biotechs including Rubius Therapeutics, which raised hundreds of millions of dollars before liquidating in 2023, and Ery…
For several billions: Bayer adds Perfuse Therapeutics to portfolio of eye therapies
The Leverkusen-based pharmaceutical and life sciences group Bayer AG is strengthening its ophthalmology pipeline with a …
Switzerland’s biotech sector defies tough markets with record revenue
The financing side also presented a stable picture: capital inflows rose slightly, by 2.1%, to CHF 2.6 billion. What sta…
Macrocycles: big is the new beautiful
What if synthetic large molecules could be designed to fit almost any receptor pocket imaginable? While this may sound l…
Swiss Windward Bio adds US$165m to its Chinese pipeline
Basel-based Windward Bio has raised $165 million to advance a pipeline of long-acting immunology therapies—much of it so…
Cytospire raises £61M to take gamma-delta T-cell engager into the clinic
Conventional TCEs bind CD3 on T cells to drive destruction of tumor cells. The modality has improved outcomes in blood c…
UCB buys Candid Therapeutics for up to US$2.2bn to deepen autoimmune T-cell engager push
The transaction, announced on 3 May, gives UCB a portfolio of bispecific antibodies designed to redirect T cells against…
BioOrbit: record seed round for in‑space drug manufacturing
A large share of the world’s top‑selling medicines are administered intravenously in clinical settings. This ties patien…